Minireviews
Copyright ©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Oct 6, 2018; 6(11): 418-425
Published online Oct 6, 2018. doi: 10.12998/wjcc.v6.i11.418
Dual HER2 inhibition strategies in the management of treatment-refractory metastatic colorectal cancer: History and status
Ozkan Kanat, Hulya Ertas, Burcu Caner
Ozkan Kanat, Hulya Ertas, Burcu Caner, Department of Medical Oncology, Faculty of Medicine, Uludag University, Bursa 16059, Turkey
Author contributions: Kanat O assigned the issue, collected relevant literature data, and wrote the manuscript; Ertas H and Caner B performed literature research and contributed to the final version of the manuscript.
Conflict-of-interest statement: No potential conflicts of interest relevant to this article were reported.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Ozkan Kanat, MD, PhD, Professor, Department of Medical Oncology, Faculty of Medicine, Uludag University, Gorukle, Bursa 16059, Turkey. ozkanat@uludag.edu.tr
Telephone: +90-224-2951321 Fax: +90-224-2951341
Received: April 10, 2018
Peer-review started: April 10, 2018
First decision: April 27, 2018
Revised: May 15, 2018
Accepted: June 8, 2018
Article in press: June 8, 2018
Published online: October 6, 2018
Processing time: 171 Days and 1.1 Hours
Core Tip

Core tip: We reviewed the preclinical studies exploring the role of human epidermal growth factor receptor 2 (HER2) signaling in the development of anti-epidermal growth factor receptor therapy resistance in metastatic colorectal cancer and discussed the status of clinical trials assessing the activity of HER2 inhibitors in this setting.